Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001209191-18-010219
Filing Date
2018-02-14
Accepted
2018-02-14 21:28:29
Documents
2
Period of Report
2018-02-13

Document Format Files

Seq Description Document Type Size
1 FORM 3 SUBMISSION doc3.html 3  
1 FORM 3 SUBMISSION doc3.xml 3 1556
2 POA DOCUMENT poa.txt EX-24.3_769126 3122
  Complete submission text file 0001209191-18-010219.txt   6387
Mailing Address 2500 NORTHWINDS PARKWAY, SUITE 100 ALPHARETTA 2Q 30009
Business Address 2500 NORTHWINDS PARKWAY, SUITE 100 ALPHARETTA 2Q 30009 301-770-3099
Aviragen Therapeutics, Inc. (Issuer) CIK: 0000072444 (see all company filings)

EIN.: 591212264 | State of Incorp.: DE | Fiscal Year End: 0630
SIC: 2836 Biological Products, (No Diagnostic Substances)

Mailing Address C/O WAFERGEN BIO-SYSTEMS, INC. 7400 PASEO PADRE PARKWAY FREMONT CA 94555
Business Address
Harland John M (Reporting) CIK: 0001546788 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-35285 | Film No.: 18615941